This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
BioMarin Stops Voxzogo Development for Noonan Syndrome
by Zacks Equity Research
BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.
BMRNNegative Net Change ASNDNegative Net Change BBIONegative Net Change
biotechs medical
How AbbVie's Neuroscience Portfolio Has Transformed Over the Years
by Sundeep Ganoria
ABBV's neuroscience portfolio has broadened across psychiatry, migraine and Parkinson's, driving strong growth and raising its 2026 outlook.
ABBVNegative Net Change BIIBNegative Net Change JNJNegative Net Change
biotechs medical pharmaceuticals
RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
by Zacks Equity Research
Rocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion.
RCKTNegative Net Change RGENNegative Net Change AMRNNegative Net Change ANIKNegative Net Change
biotechs
Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America
by Zacks Equity Research
GILD's PAHO deal expands twice-yearly lenacapavir access across Latin America and the Caribbean, adding 14 countries to its global access strategy.
GILDNegative Net Change ALDXNegative Net Change ACIUNegative Net Change PGENNegative Net Change
biotechnology biotechs medical pharmaceuticals
Is Cancer the Turnaround Moderna Has Been Looking for Post-COVID?
by Zacks Equity Research
Cancer progress, a broader pipeline and vaccine expansion help MRNA rebuild beyond COVID-19, but can oncology drive its next growth phase?
MRNANegative Net Change PFEPositive Net Change MRKNegative Net Change NVAXPositive Net Change
biotechs medical pharmaceuticals vaccines
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study
by Zacks Equity Research
IMCR achieves target enrollment in the phase III TEBE-AM study investigating Kimmtrak in previously treated patients with advanced melanoma.
IMCRNegative Net Change MRKNegative Net Change ANIKNegative Net Change PGENNegative Net Change
biotechs
Definium Reports Second Phase III Success in Anxiety Disorder Program
by Zacks Equity Research
DFTX scores a second phase III GAD win as DT120 ODT delivers significant anxiety improvements, paving the way for FDA talks and a planned 2027 regulatory filing.
DFTXPositive Net Change ALDXNegative Net Change ACIUNegative Net Change PGENNegative Net Change
biotechnology biotechs medical pharmaceuticals
4 Prostate Cancer Drug Stocks to Watch During Awareness Month
by Ahan Chakraborty
Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.
NVSNegative Net Change PFEPositive Net Change JANXNegative Net Change CADLNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
4 Value Stocks to Buy as Oil Surge Fuels Fed Rate Hike Fears
by Rimmi Singhi
Unlock your portfolio value by investing in high earnings yield stocks like Ternium, Halozyme, POSCO and Talos Energy.
PKXNegative Net Change HALOPositive Net Change TXNegative Net Change TALONegative Net Change
basic-materials biotechs energy oil-energy
INCY Stock Gains 23% Year to Date: Buy, Sell or Hold?
by Zacks Equity Research
Incyte's strong product demand and pipeline progress fuel its 23% YTD rally, but valuation and near-term earnings pressure temper the outlook.
INCYNegative Net Change GSKNegative Net Change NVSNegative Net Change
biotechnology biotechs pharmaceuticals